organ transplant
Natera Inks Distribution Deal With TomaLab for Italy
The deal covers three of Natera's tests including its Signatera circulating tumor DNA test for cancer treatment monitoring and minimal residual disease assessment.
Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection
Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status.
CareDx Acquires European Transplant Surveillance Software Firm BFS Molecular
The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.
The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.
CareDx Q4 Revenues Up 64 Percent
The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.
Jan 21, 2021
CareDx Prices $175M Common Stock Offering
Oct 29, 2020
CareDx Q3 Revenues Up 58 Percent
Oct 7, 2020